AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
BCR-ABL negative myeloproliferative neoplasms (MPNs) consist of essential thrombocythemia, polycythemia vera, and myelofibrosis. The majority of patients harbor the JAK2-activating mutation V617F. JAK2 inhibitors were shown to reduce symptom burden and splenomegaly in MPN patients. However, treatmen...
Main Authors: | Antonia Beitzen-Heineke, Nikolaus Berenbrok, Jonas Waizenegger, Sarina Paesler, Victoria Gensch, Florian Udonta, Maria Elena Vargas Delgado, Janik Engelmann, Friederike Hoffmann, Philippe Schafhausen, Gunhild von Amsberg, Kristoffer Riecken, Niklas Beumer, Charles D. Imbusch, James Lorens, Thomas Fischer, Klaus Pantel, Carsten Bokemeyer, Isabel Ben-Batalla, Sonja Loges |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000630 |
Similar Items
-
Regulation of bone homeostasis by MERTK and TYRO3
by: Janik Engelmann, et al.
Published: (2022-12-01) -
The Role of TAM Receptors in Bone
by: Janik Engelmann, et al.
Published: (2023-12-01) -
BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
by: Aleksandra Mroczkowska-Bękarciak, et al.
Published: (2023-09-01) -
The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy
by: Strickland, M, et al.
Published: (2021) -
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
by: Enrico La Spina, et al.
Published: (2023-02-01)